title: Cutaneous sarcoidosis in a patient with ulcerative colitis on infliximab.
abstract: The advance of anti-tumour necrosis factor (TNF) therapy had dramatically changed the treatment algorithm of inflammatory bowel disease (IBD). This had significantly improved the quality of life for patients with Crohn's disease (CD) and ulcerative colitis (UC).(1) However, side-effects of anti-TNF treatment were unavoidable with paradoxical inflammation (for example leucocytoclastic vasculitis and psoriasis) being well-known phenomena of anti-TNF therapy.(2) We report a case of infliximab induced cutaneous sarcoidosis in a patient with ulcerative colitis and review the literature.
authors.affiliation: Department of Gastroenterology, Campbelltown Hospital, NSW, Australia University of Western Sydney, NSW, Australia. drianfok@gmail.com
authors.forename: Kum C
authors.initials: KC
authors.lastname: Fok
authors.forename: Watson W S
authors.initials: WW
authors.lastname: Ng
authors.forename: Christopher J A
authors.initials: CJ
authors.lastname: Henderson
authors.forename: Susan J
authors.initials: SJ
authors.lastname: Connor
mesh_terms: D000368:Aged; D000893:Anti-Inflammatory Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D003093:Colitis, Ulcerative / Q000150:complications / Q000188:drug therapy*; D005260:Female; D006801:Humans; D000069285:Infliximab; D012507:Sarcoidosis / Q000139:chemically induced* / Q000175:diagnosis; D012871:Skin Diseases / Q000139:chemically induced* / Q000175:diagnosis
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D000069285:Infliximab